Key Highlights
- Alloy Therapeutics licenses ATX-Gx™ and ATX-CLC™ platforms to Eli Lilly.
- Non-exclusive agreement supports antibody drug discovery and development.
- Partnership enhances Lilly’s Catalyze360™ program for biotech innovation.
- Alloy platforms utilized by over 170 partners in therapeutic discovery.
Source: Business Wire
Notable Quote
- “Lilly is a great collaboration partner, and we are excited to further enable the company’s broader R&D ecosystem with access to Alloy’s best-in-class technologies for discovering superior fully human antibodies and bispecifics against even the most challenging targets,” – Heather Schwoebel, CBO of Antibodies and Strategic Collaborations at Alloy
SoHC's Take
This licensing agreement between Alloy Therapeutics and Eli Lilly signifies a strategic alignment that leverages Alloy’s advanced murine platforms to bolster Lilly’s R&D capabilities. The non-exclusive nature of the license allows for broad utilization of Alloy’s ATX-Gx™ and ATX-CLC™ platforms, which are recognized as industry standards for fully human antibody discovery. By integrating these technologies into its Catalyze360™ program, Lilly can significantly accelerate its drug discovery and development processes, providing biotech partners with cutting-edge tools and expertise. This collaboration underscores the importance of innovative platform technologies in driving forward the development of next-generation therapeutics and enhancing patient outcomes.
